Literature DB >> 25965572

Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.

Robert S Welner1, Giovanni Amabile1, Deepak Bararia2, Akos Czibere1, Henry Yang2, Hong Zhang1, Lorena Lobo De Figueiredo Pontes1, Min Ye1, Elena Levantini3, Annalisa Di Ruscio1, Giovanni Martinelli4, Daniel G Tenen5.   

Abstract

Leukemic cells disrupt normal patterns of blood cell formation, but little is understood about the mechanism. We investigated whether leukemic cells alter functions of normal hematopoietic stem and progenitor cells. Exposure to chronic myelogenous leukemia (CML) caused normal mouse hematopoietic progenitor cells to divide more readily, altered their differentiation, and reduced their reconstitution and self-renewal potential. Interestingly, the normal bystander cells acquired gene expression patterns resembling their malignant counterparts. Therefore, much of the leukemia signature is mediated by extrinsic factors. Indeed, IL-6 was responsible for most of these changes. Compatible results were obtained when human CML were cultured with normal human hematopoietic progenitor cells. Furthermore, neutralization of IL-6 prevented these changes and treated the disease.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25965572      PMCID: PMC4447336          DOI: 10.1016/j.ccell.2015.04.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  53 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair.

Authors:  Anne Wilson; Elisa Laurenti; Gabriela Oser; Richard C van der Wath; William Blanco-Bose; Maike Jaworski; Sandra Offner; Cyrille F Dunant; Leonid Eshkind; Ernesto Bockamp; Pietro Lió; H Robson Macdonald; Andreas Trumpp
Journal:  Cell       Date:  2008-12-12       Impact factor: 41.582

3.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

4.  Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells.

Authors:  Angela Colmone; Maria Amorim; Andrea L Pontier; Sheng Wang; Elizabeth Jablonski; Dorothy A Sipkins
Journal:  Science       Date:  2008-12-19       Impact factor: 47.728

5.  Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.

Authors:  X Zhang; R Ren
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

6.  The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.

Authors:  F Dazzi; D Capelli; R Hasserjian; F Cotter; M Corbo; A Poletti; W Chinswangwatanakul; J M Goldman; M Y Gordon
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

7.  Kinetics of normal hematopoietic stem and progenitor cells in a Notch1-induced leukemia model.

Authors:  Xiaoxia Hu; Hongmei Shen; Chen Tian; Hui Yu; Guoguang Zheng; Richard XuFeng; Zhenyu Ju; Jing Xu; Jianmin Wang; Tao Cheng
Journal:  Blood       Date:  2009-08-03       Impact factor: 22.113

8.  MCP-1, not MIP-1alpha, is the endogenous chemokine that cooperates with TGF-beta to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures.

Authors:  J D Cashman; C J Eaves; A H Sarris; A C Eaves
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

Review 9.  Mouse hematopoietic stem cell identification and analysis.

Authors:  Grant A Challen; Nathan Boles; Karen Kuan-Yin Lin; Margaret A Goodell
Journal:  Cytometry A       Date:  2009-01       Impact factor: 4.355

10.  Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia.

Authors:  Marc H G P Raaijmakers; Siddhartha Mukherjee; Shangqin Guo; Siyi Zhang; Tatsuya Kobayashi; Jesse A Schoonmaker; Benjamin L Ebert; Fatima Al-Shahrour; Robert P Hasserjian; Edward O Scadden; Zinmar Aung; Marc Matza; Matthias Merkenschlager; Charles Lin; Johanna M Rommens; David T Scadden
Journal:  Nature       Date:  2010-03-21       Impact factor: 49.962

View more
  54 in total

Review 1.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

2.  Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis.

Authors:  Zhigang Cai; Jonathan J Kotzin; Baskar Ramdas; Sisi Chen; Sai Nelanuthala; Lakshmi Reddy Palam; Ruchi Pandey; Raghuveer Singh Mali; Yan Liu; Mark R Kelley; George Sandusky; Morvarid Mohseni; Adam Williams; Jorge Henao-Mejia; Reuben Kapur
Journal:  Cell Stem Cell       Date:  2018-12-06       Impact factor: 24.633

3.  Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.

Authors:  Alice Giustacchini; Supat Thongjuea; Nikolaos Barkas; Petter S Woll; Benjamin J Povinelli; Christopher A G Booth; Paul Sopp; Ruggiero Norfo; Alba Rodriguez-Meira; Neil Ashley; Lauren Jamieson; Paresh Vyas; Kristina Anderson; Åsa Segerstolpe; Hong Qian; Ulla Olsson-Strömberg; Satu Mustjoki; Rickard Sandberg; Sten Eirik W Jacobsen; Adam J Mead
Journal:  Nat Med       Date:  2017-05-15       Impact factor: 53.440

Review 4.  Hematopoietic Stem Cell and Its Bone Marrow Niche.

Authors:  V W C Yu; D T Scadden
Journal:  Curr Top Dev Biol       Date:  2016-03-21       Impact factor: 4.897

5.  Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.

Authors:  Pingnan Xiao; Monika Dolinska; Lakshmi Sandhow; Makoto Kondo; Anne-Sofie Johansson; Thibault Bouderlique; Ying Zhao; Xidan Li; Marios Dimitriou; George Z Rassidakis; Eva Hellström-Lindberg; Nagahiro Minato; Julian Walfridsson; David T Scadden; Mikael Sigvardsson; Hong Qian
Journal:  Blood Adv       Date:  2018-03-13

Review 6.  Inflammation: a key regulator of hematopoietic stem cell fate in health and disease.

Authors:  Eric M Pietras
Journal:  Blood       Date:  2017-09-05       Impact factor: 22.113

7.  Defining niche interactions to target chronic myeloid leukemia stem cells.

Authors:  Rebecca Mitchell; Mhairi Copland
Journal:  Haematologica       Date:  2020-01       Impact factor: 9.941

Review 8.  Metabolic underpinnings of leukemia pathology and treatment.

Authors:  Travis Nemkov; Angelo D'Alessandro; Julie A Reisz
Journal:  Cancer Rep (Hoboken)       Date:  2018-10-07

9.  Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.

Authors:  Anne-Sophie Bouillon; Monica S Ventura Ferreira; Shady Adnan Awad; Johan Richter; Andreas Hochhaus; Volker Kunzmann; Jolanta Dengler; Jeroen Janssen; Gert Ossenkoppele; Peter E Westerweel; Peter A W Te Boekhorst; Francois-Xavier Mahon; Henrik Hjorth-Hansen; Susanne Isfort; Thoas Fioretos; Sebastian Hummel; Mirle Schemionek; Stefan Wilop; Steffen Koschmieder; Susanne Saußele; Satu Mustjoki; Fabian Beier; Tim H Brümmendorf
Journal:  Blood Adv       Date:  2018-07-10

10.  Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches.

Authors:  Peter William Krenn; Steffen Koschmieder; Reinhard Fässler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.